Pharsight

Drugs that contain Raltegravir Potassium

1. Isentress patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7169780 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2023

(5 months ago)

US7754731 MERCK SHARP DOHME Potassium salt of an HIV integrase inhibitor
Mar, 2029

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7217713 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2022

(1 year, 5 months ago)

US7435734 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2022

(1 year, 5 months ago)

US7435734

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2023

(11 months ago)

US7217713

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2023

(11 months ago)

US7169780

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2024

(4 days from now)

US7754731

(Pediatric)

MERCK SHARP DOHME Potassium salt of an HIV integrase inhibitor
Sep, 2029

(5 years from now)

US9649311 MERCK SHARP DOHME Solid pharmaceutical compositions containing an integrase inhibitor
Oct, 2030

(6 years from now)

US9649311

(Pediatric)

MERCK SHARP DOHME Solid pharmaceutical compositions containing an integrase inhibitor
Apr, 2031

(7 years from now)

US10772888 MERCK SHARP DOHME Solid pharmaceutical compositions containing an integrase inhibitor
Mar, 2032

(8 years from now)

Market Authorisation Date: 12 October, 2007

Treatment: Treatment of hiv infection; Integrase inhibition for the treatment of hiv infection; Treatment of hiv-1 infection

Dosage: TABLET;ORAL

How can I launch a generic of ISENTRESS before it's drug patent expiration?
More Information on Dosage

ISENTRESS family patents

Family Patents

2. Isentress patents expiration

ISENTRESS's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8852632 MSD SUB MERCK Pharmaceutical formulation containing a release rate controlling composition
Jan, 2028

(3 years from now)

US8771733 MSD SUB MERCK Pharmaceutical composition containing an anti-nucleating agent
Jun, 2030

(6 years from now)

Market Authorisation Date: 12 October, 2007

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of ISENTRESS before it's drug patent expiration?
More Information on Dosage

ISENTRESS family patents

Family Patents